modelR05DA05

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:OpiumAlkaloidsWithMorphine
ATC code:R05DA05
route:oral
compartments:1
dosage:10mg
volume of distribution:4L
clearance:60L/h
other parameters in model implementation

Opium alkaloids with morphine comprise a combination of opium-derived alkaloids, predominantly morphine, used historically as antitussive (cough suppressant) agents. The combination acts primarily through opioid receptors, providing relief from severe cough. Given the potential for abuse and side effects, its use is now largely obsolete or restricted in many countries, replaced by safer alternatives. It is not widely approved for use today.

Pharmacokinetics

Pharmacokinetic parameters are estimated based on typical oral morphine preparations in adults, as no specific population PK model or clinical study of pharmacokinetics for this fixed combination is available.

References

  1. Lugo, RA, & Kern, SE (2002). Clinical pharmacokinetics of morphine. Journal of pain & palliative care pharmacotherapy 16(4) 5–18. DOI:10.1080/j354v16n04_02 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14635822

  2. Lugo, RA, & Kern, SE (2004). The pharmacokinetics of oxycodone. Journal of pain & palliative care pharmacotherapy 18(4) 17–30. DOI:10.1300/j354v18n04_03 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15760805

  3. Liu, T, et al., & Ivaturi, V (2016). Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium. Journal of clinical pharmacology 56(8) 1009–1018. DOI:10.1002/jcph.696 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26712409

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)